SGLT-2抑制剂达格列净治疗早期糖尿病肾病的临床效果和安全性分析  

Clinical Efficacy and Safety of SGLT-2 Inhibitor Dapagliflozin in the Treatment of Early Diabetic Nephropathy

作　　者：刘泮力[1] LIU Panli(Department of Endocrinology,Beijing Sixth Hospital,Beijing,100007 China)

机构地区：[1]北京市第六医院内分泌科,北京100007

出　　处：《糖尿病新世界》2024年第6期9-11,22,共4页Diabetes New World Magazine

摘　　要：目的分析在早期糖尿病肾病治疗中采用钠-葡萄糖协同转运蛋白2(Sodium-dependent Glucose Transporters 2,SGLT-2)抑制剂达格列净的疗效和安全性。方法选取2022年3月—2023年12月北京市第六医院收治的100例早期糖尿病肾病患者为研究对象,以随机数表法分为研究组和对照组,各50例。给予全部患者常规治疗,研究组加用达格列净治疗,对照组加用二甲双胍治疗,对比两组血糖水平、肾功能和不良反应发生情况。结果治疗后,研究组空腹血糖为(5.16±0.77)mmol/L,餐后2 h血糖为(7.11±1.38)mmol/L,糖化血红蛋白为(5.05±0.73)%,低于对照组,差异有统计学意义(t=4.592、5.020、5.093,P均<0.05)。治疗后,研究组尿白蛋白/肌酐比值、肾小球过滤率优于对照组,差异有统计学意义(P均<0.05)。研究组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论在早期糖尿病肾病治疗中采用SGLT-2抑制剂达格列净疗效显著,可以有效降低血糖水平,改善肾功能,降低不良反应发生率。Objective To analyze the efficacy and safety of sodium-dependent glucose transporters 2(SGLT-2)inhibitor dapagliflozin in the treatment of early diabetic nephropathy.Methods 100 early diabetic nephropathy patients admitted to Beijing Sixth Hospital from March 2022 to December 2023 were selected as the study objects.According to the method of random number table,they were divided into the study group and the control group,with 50 cases in each group.All patients were given routine treatment,dapagliflozin was added in the study group and metformin was added in the control group.Blood glucose levels,renal function and adverse reactions were compared between two groups.Results The fasting blood glucose in the study group was(5.16±0.77)mmol/L,2 h postprandial blood glucose was(7.11±1.38)mmol/L,glycosylated hemoglobin A1c was(5.05±0.73)%,which were lower than those of the control group,the differences were statistically significant(t=4.592,5.020,5.093,all P<0.05).Urine albumin/creatine ratio and glomerular filtration rate in the study group after treatment were better than those of the control group,the differences were statistically significant(both P<0.05).The incidence of adverse reactions in study group was lower than that in control group,the difference was statistically significant(P<0.05).Conclusion The use of SGLT-2 inhibitor dapagliflozin in the treatment of early diabetic nephropathy has a significant effect,which can reduce blood glucose level,improve the renal function,and reduce the incidence of adverse reactions.

关 键 词：钠-葡萄糖协同转运蛋白2抑制剂 达格列净 早期糖尿病肾病 

分 类 号：R587[医药卫生—内分泌]